Glaxosmithkline Pharmaceuticals Q3 FY24 Results Live : profit falls by 72.22% YOY
Glaxosmithkline Pharmaceuticals Q3 FY24 Results Live : Revenue increased by 0.37% YoY & profit decreased by 72.22% YoY
Glaxosmithkline Pharmaceuticals declared their Q3 FY24 results on 12 Feb, 2024. The topline increased by 0.37% & the profit decreased by 72.22% YoY. As compared to the previous quarter the revenue declined by 15.85% and the profit decreased by 78.98%.
The Selling, general & administrative expenses declined by 2.66% q-o-q & decreased by 7.61% Y-o-Y.
The operating income was down by 86.13% q-o-q & decreased by 81.27% Y-o-Y.
The EPS is ₹9.44 for Q3 FY24 which decreased by 7.48% Y-o-Y.
Glaxosmithkline Pharmaceuticals has delivered -4.41% return in the last 1 week, 65.37% return in last 6 months and 23.29% YTD return.
Currently the Glaxosmithkline Pharmaceuticals has a market cap of ₹39643.55 Cr and 52wk high/low of ₹2524 & ₹1227 respectively.
As of 14 Feb, 2024 out of 5 analysts covering the company, 4 analysts have given Hold rating &1 analyst has given Strong Buy rating.
The consensus recommendation as on 14 Feb, 2024 was to Hold.
Glaxosmithkline Pharmaceuticals Financials
| Period | Q3 FY24 | Q2 FY24 | Q-o-Q Growth | Q3 FY23 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 805.26 | 956.99 | -15.85% | 802.3 | +0.37% |
| Selling/ General/ Admin Expenses Total | 141.35 | 145.21 | -2.66% | 152.99 | -7.61% |
| Depreciation/ Amortization | 17.11 | 18.11 | -5.52% | 16.41 | +4.27% |
| Total Operating Expense | 767.62 | 685.61 | +11.96% | 601.38 | +27.64% |
| Operating Income | 37.64 | 271.38 | -86.13% | 200.92 | -81.27% |
| Net Income Before Taxes | 65.43 | 299.16 | -78.13% | 224.25 | -70.82% |
| Net Income | 45.72 | 217.51 | -78.98% | 164.56 | -72.22% |
| Diluted Normalized EPS | 9.44 | 12.84 | -26.49% | 10.2 | -7.48% |
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.